-
Company Insights
Innovation and Patenting activity of TD SYNNEX Corp Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of TD SYNNEX Corp Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Pramipexole in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pramipexole in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pramipexole in Parkinson's Disease Drug Details: Pramipexole is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ampreloxetine Hydrochloride in Orthostatic Hypotension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ampreloxetine Hydrochloride in Orthostatic Hypotension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ampreloxetine Hydrochloride in Orthostatic Hypotension Drug Details: Ampreloxetine HCL (TD-9855) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TD-5202 in Ulcerative Colitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TD-5202 in Ulcerative Colitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.TD-5202 in Ulcerative Colitis Drug Details:TD-5202 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TD-5202 in Crohn’s Disease (Regional Enteritis)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TD-5202 in Crohn's Disease (Regional Enteritis) Drug Details: TD-5202 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ieramilimab in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ieramilimab in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ieramilimab in Solid Tumor Drug Details: Ieramilimab (LAG-525) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Umitrelimorgene Autodencel in Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Umitrelimorgene Autodencel in Glioblastoma Multiforme (GBM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Umitrelimorgene Autodencel in Glioblastoma Multiforme (GBM) Drug Details: Umitrelimorgene autodencel...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AGI-134 in Cervical Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AGI-134 in Cervical Cancer Drug Details: AGI-134 is under development for the treatment of solid...
-
Analyst Opinions
Immersive Enterprise – Sector Impact of Alternative Reality Technologies
Immersive Enterprise – Sector Impact of Alternative Reality Technologies Report Overview The immersive platform landscape is being shaped by a host of convergent trends, such as advanced hardware, 5G roll-out, cloud computing, miniaturization, and collaborative features among others. This report serves as an invaluable resource for gaining insights into how the adoption of immersive platforms not only enhances user experiences but also cultivates customer-centric strategies. In addition, the report highlights advantages, such as fostering greater engagement, accelerating training and learning,...